


PHARMACEUTICAL 2019

Dicerna Pharmaceuticals Inc Rank 107 of 371





PHARMACEUTICAL 2019

Dicerna Pharmaceuticals Inc Rank 107 of 371

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 172% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Revenues, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is -45%, being 286% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	405,514
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	94,055
Liabilities, Non-Current	114,293
Other Assets	809
Other Compr. Net Income	0
Other Expenses	29,132
Other Liabilities	0
Other Net Income	1,499
Property and Equipment	2,718
Research and Development	45,711
Revenues	6,176
Selling, General and Administrative Expense	21,685

Output Variable	Value in 1000 USD
Assets	409,041
Liabilities	208,348
Expenses	96,528
Stockholders Equity	200,693
Net Income	-88,853
Comprehensive Net Income	-88,853
Economic Capital Ratio	-45%